SK9972001A3 - Quinolizine derivative, pharmaceutical composition containing same and use thereof - Google Patents

Quinolizine derivative, pharmaceutical composition containing same and use thereof Download PDF

Info

Publication number
SK9972001A3
SK9972001A3 SK997-2001A SK9972001A SK9972001A3 SK 9972001 A3 SK9972001 A3 SK 9972001A3 SK 9972001 A SK9972001 A SK 9972001A SK 9972001 A3 SK9972001 A3 SK 9972001A3
Authority
SK
Slovakia
Prior art keywords
carboxylic acid
quinolizine
decahydro
methyl
benzopyrano
Prior art date
Application number
SK997-2001A
Other languages
English (en)
Slovak (sk)
Inventor
Geraldine C Harriman
Christine Nylund Kolz
Jay R Luly
Bruce David Roth
Yuntao Song
Bharat Kalidas Trivedi
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of SK9972001A3 publication Critical patent/SK9972001A3/sk

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D455/00Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
    • C07D455/02Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing not further condensed quinolizine ring systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
SK997-2001A 1999-01-13 1999-12-20 Quinolizine derivative, pharmaceutical composition containing same and use thereof SK9972001A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11565499P 1999-01-13 1999-01-13
PCT/US1999/030434 WO2000042045A2 (en) 1999-01-13 1999-12-20 Functionalized heterocycles as chemokine receptor modulators

Publications (1)

Publication Number Publication Date
SK9972001A3 true SK9972001A3 (en) 2002-03-05

Family

ID=22362668

Family Applications (1)

Application Number Title Priority Date Filing Date
SK997-2001A SK9972001A3 (en) 1999-01-13 1999-12-20 Quinolizine derivative, pharmaceutical composition containing same and use thereof

Country Status (20)

Country Link
EP (1) EP1144415A2 (ru)
JP (1) JP2002534526A (ru)
KR (1) KR20010086166A (ru)
CN (1) CN1344270A (ru)
AP (1) AP2001002228A0 (ru)
AU (1) AU1940900A (ru)
BR (1) BR9916905A (ru)
CA (1) CA2372197A1 (ru)
CZ (1) CZ20012502A3 (ru)
EA (1) EA200100774A1 (ru)
HK (1) HK1044539A1 (ru)
HU (1) HUP0202932A3 (ru)
IL (1) IL144289A0 (ru)
MX (1) MXPA01007033A (ru)
NO (1) NO20013456L (ru)
OA (1) OA11820A (ru)
PL (1) PL349348A1 (ru)
SK (1) SK9972001A3 (ru)
WO (1) WO2000042045A2 (ru)
ZA (1) ZA200106592B (ru)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1377549A1 (en) * 2001-03-12 2004-01-07 Millennium Pharmaceuticals, Inc. Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor
EA007493B1 (ru) 2001-03-29 2006-10-27 Эли Лилли Энд Компани N-(2-арилэтил)бензиламины в качестве антагонистов 5-ht-рецептора
WO2003035650A1 (fr) * 2001-09-25 2003-05-01 Takeda Chemical Industries, Ltd. Inhibiteur d'entree
WO2004080966A1 (ja) 2003-03-14 2004-09-23 Ono Pharmaceutical Co., Ltd. 含窒素複素環誘導体およびそれらを有効成分とする薬剤
EP1619193A4 (en) 2003-04-18 2010-08-11 Ono Pharmaceutical Co SPIROPIPERIDINE COMPOUND AND MEDICINAL USE THEREOF
NZ553696A (en) 2004-09-13 2010-02-26 Ono Pharmaceutical Co Nitrogenous heterocyclic derivative and medicine containing the same as an active ingredient
WO2006129679A1 (ja) 2005-05-31 2006-12-07 Ono Pharmaceutical Co., Ltd. スピロピペリジン化合物およびその医薬用途
WO2007031838A1 (en) 2005-09-16 2007-03-22 Ranbaxy Laboratories Limited Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors
PT1942108E (pt) 2005-10-28 2013-10-24 Ono Pharmaceutical Co Composto com um grupo básico e a sua utilização
ES2407115T3 (es) 2005-11-18 2013-06-11 Ono Pharmaceutical Co., Ltd. Compuesto que contiene un grupo básico y uso del mismo
CN101460458A (zh) 2006-02-15 2009-06-17 阿勒根公司 具有1-磷酸-鞘氨醇(s1p)受体拮抗剂生物活性的带芳基或者杂芳基基团的吲哚-3-羧酸的酰胺、酯、硫代酰胺和硫羟酸酯化合物
CA2642668C (en) * 2006-02-15 2013-01-08 Allergan, Inc. Indole-3-carboxylic acid amide and ester compounds bearing phenyl groups having sphingosine-1-phosphate (s1p) receptor antagonist biological activity
AU2007225836A1 (en) 2006-03-10 2007-09-20 Ono Pharmaceutical Co., Ltd. Nitrogenated heterocyclic derivative, and pharmaceutical agent comprising the derivative as active ingredient
EP2042503B1 (en) 2006-05-16 2013-01-30 Ono Pharmaceutical Co., Ltd. Compound having acidic group which may be protected, and use thereof
EA016633B1 (ru) 2006-05-23 2012-06-29 Общество С Ограниченной Ответственностью "Инновационная Фармацевтика" Замещенные индолы, способ их получения и применения
WO2008016006A1 (en) 2006-07-31 2008-02-07 Ono Pharmaceutical Co., Ltd. Compound having cyclic group bound thereto through spiro binding and use thereof
CA2674946A1 (en) * 2007-01-11 2008-07-24 Allergan, Inc. 6-substituted indole-3-carboxylic acid amide compounds having sphingosine-1-phosphate (s1p) receptor antagonist biological activity
US8524917B2 (en) 2007-01-11 2013-09-03 Allergan, Inc. 6-substituted indole-3-carboxylic acid amide compounds having sphingosine-1-phosphate (S1P) receptor antagonist biological activity
WO2010129351A1 (en) 2009-04-28 2010-11-11 Schepens Eye Research Institute Method to identify and treat age-related macular degeneration
US8293738B2 (en) 2010-05-12 2012-10-23 Abbott Laboratories Indazole inhibitors of kinase
EP2741777B1 (en) 2011-08-12 2017-01-18 INSERM - Institut National de la Santé et de la Recherche Médicale Methods and pharmaceutical compositions for treatment of pulmonary hypertension
JO3459B1 (ar) 2012-09-09 2020-07-05 H Lundbeck As تركيبات صيدلانية لعلاج مرض الزهايمر
CN104193669B (zh) * 2014-08-01 2016-12-07 大连理工大学 一类阿比朵尔类似物或其盐、其制备方法及应用
WO2016112088A1 (en) * 2015-01-06 2016-07-14 Spero Therapeutics, Inc. Aryloxyacetylindoles and analogs as antibiotic tolerance inhibitors
CN110256324A (zh) * 2019-06-13 2019-09-20 苏州莱安医药化学技术有限公司 一种2-甲基-5-羟基吲哚的制备方法
US11629196B2 (en) 2020-04-27 2023-04-18 Incelldx, Inc. Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3549641A (en) * 1966-06-28 1970-12-22 Warner Lambert Pharmaceutical Pyrano pyridines and process for their production
US3518258A (en) * 1967-05-09 1970-06-30 Warner Lambert Pharmaceutical Pyrano(3,2-i)quinolizine and process for the production
US3565903A (en) * 1967-11-24 1971-02-23 Warner Lambert Pharmaceutical Pyrano(2,3-b)quinolines and process for their production
US5635510A (en) * 1993-05-06 1997-06-03 Merrell Pharmaceuticals Inc. Substituted pyrrolidin-3-yl-alkyl-piperidines
HRP960352A2 (en) * 1996-07-26 1998-08-31 Pliva Pharm & Chem Works Novel coumarin quinoline carboxylic acids
KR100447553B1 (ko) * 1997-02-26 2004-09-08 화이자 인코포레이티드 헤테로아릴-헥사노산 아미드 유도체, 그의 제조 방법 및 mip-1 알파의 ccr1 수용체로의 결합에 대한 선택적 저해제로서의 용도
EP1052992A1 (en) * 1998-02-02 2000-11-22 Merck & Co., Inc. Cyclic amine modulators of chemokine receptor activity

Also Published As

Publication number Publication date
HK1044539A1 (zh) 2002-10-25
MXPA01007033A (es) 2003-07-21
HUP0202932A3 (en) 2003-07-28
PL349348A1 (en) 2002-07-15
JP2002534526A (ja) 2002-10-15
HUP0202932A2 (hu) 2002-12-28
NO20013456D0 (no) 2001-07-12
AP2001002228A0 (en) 2001-09-30
CN1344270A (zh) 2002-04-10
OA11820A (en) 2005-08-17
WO2000042045A3 (en) 2000-11-09
IL144289A0 (en) 2002-05-23
KR20010086166A (ko) 2001-09-08
WO2000042045A2 (en) 2000-07-20
CA2372197A1 (en) 2000-07-20
EA200100774A1 (ru) 2002-02-28
CZ20012502A3 (cs) 2002-03-13
NO20013456L (no) 2001-09-12
EP1144415A2 (en) 2001-10-17
AU1940900A (en) 2000-08-01
ZA200106592B (en) 2002-08-12
BR9916905A (pt) 2002-01-29

Similar Documents

Publication Publication Date Title
SK9972001A3 (en) Quinolizine derivative, pharmaceutical composition containing same and use thereof
EP1467970B1 (en) Hydroxynaphthyridinone carboxamides useful as hiv integrase inhibitors
WO2022031678A1 (en) Kras g12d inhibitors
DE60128936T2 (de) Aza- und polyaza-naphthalenylcarbonsäureamide als hiv-integrase-hemmer
JPH0386875A (ja) アザビシクロキノロンカルボン酸
KR20180037265A (ko) Parp 억제제로서의 헤테로아릴 유도체
KR20070053313A (ko) 화합물
MXPA02000978A (es) Antagonistas del receptor de quimioquina y metodosde uso de los mismos.
TW200407143A (en) Pyrrolotriazinone compounds and their use to treat diseases
JP2008511669A6 (ja) 化合物
JP3170584B2 (ja) 新規なイサチンオキシム誘導体類、その製造および使用
PL85030B1 (ru)
CZ300160B6 (cs) Deriváty galanthaminu, zpusob výroby techto derivátu, lécivo, které tyto deriváty obsahuje, použitítechto derivátu pro výrobu léciva, zpusob výroby tohoto léciva a zpusob separace (+)- a (-)-izomeruuvedených derivátu
WO2003077857A2 (en) N-(substituted benzyl)-8-hydroxy-1,6-naphthyridine-7- carboxamides useful as hiv integrase inhibitors
JPH0311067A (ja) 興奮性アミノ酸拮抗剤
AU631723B2 (en) Tricyclic-cyclic amines as novel cholinesterase inhibitors
Chacun-Lefèvre et al. Ring closure metathesis of indole 2-carboxylic acid allylamide derivatives
WO2011014098A1 (ru) Производные гидрированных пиpидo[4,3-b]индoлoв, фармацевтическая композиция, способы получения и применения
TW462964B (en) Guanidine derivatives for the treatment and prevention of disorders caused by inhibiting hyperactivity of Na/H exchange transport system and process for producing the same
DD252376A5 (de) Verfahren zur herstellung von hexohydro-(1)-benzo-(pyrane und thiopyrano)-4,3-c)pyridinen
JPH0322390B2 (ru)
WO1993022286A1 (en) Novel tetracyclic compound
Jokela et al. Synthesis of compounds in the eburnamonine-homoeburnamonine series
Varlamov et al. Intramolecular [4+ 2] cycloaddition of furfurylsubstituted homoallylamines to allylhalides, acryloyl chloride and maleic anhydride
Tadic et al. Probes for narcotic receptor mediated phenomena. Part 31: Synthesis of rac-(3R, 6aS, 11aS)-2-methyl-1, 3, 4, 5, 6, 11a-hexahydro-2H-3, 6a-methanobenzofuro [2, 3-c] azocine-10-ol, and azocine-8-ol, the ortho-c and the para-c oxide-bridged phenylmorphan isomers